Section Arrow
Quote
KALV.NASDAQ
- KalVista Pharmaceuticals
Quotes are at least 15-min delayed:2025/07/16 00:55 EDT
Regular Hours
Last
 15.17
-0.05 (-0.33%)
Day High 
15.24 
Prev. Close
15.22 
1-M High
16.32 
Volume 
1.42M 
Bid
14.25
Ask
15.24
Day Low
14.665 
Open
15.24 
1-M Low
9.83 
Market Cap 
760.30M 
Currency USD 
P/E -- 
%Yield 2.05 
10-SMA 13.79 
20-SMA 12.94 
50-SMA 12.71 
52-W High 16.32 
52-W Low 7.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.69/-0.15
Enterprise Value
764.63M
Balance Sheet
Book Value Per Share
1.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KAPAKairos Pharma Ltd.1.17+0.4849+70.78%-- 
NCNANuCana plc0.0502+0.0043+9.37%-- 
PLRZPolyrizon Ltd1.04+0.3579+52.47%-- 
CYCCCyclacel Pharmaceuticals Inc12.33+9.02+272.51%0.08PE
IOVAIovance Biotherapeutics1.94-0.07-3.48%-- 
Quotes are at least 15-min delayed：2025/07/16 00:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.